Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Compumedics Limited ( (AU:CMP) ).
Compumedics Limited has announced significant sales of its Somfit devices to major pharmaceutical and clinical research organizations in the USA and Europe, with revenues nearing $2 million. These sales mark a strategic expansion into the pharmaceutical clinical trial market, showcasing Somfit’s advanced capabilities in sleep monitoring and its potential beyond traditional home sleep testing. The contracts underscore the growing importance of sleep data in drug trials and highlight Compumedics’ commitment to diversifying its global business and exploring new growth avenues.
More about Compumedics Limited
Compumedics Limited is a global medical device company that develops, manufactures, and commercializes diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. With subsidiaries in the US and Germany, the company has a broad international reach, including the Americas, Australia, Asia Pacific, Europe, and the Middle East. Founded in 1987, Compumedics has been recognized for its innovation and export achievements.
Average Trading Volume: 72,834
Technical Sentiment Signal: Buy
Current Market Cap: A$68.24M
Find detailed analytics on CMP stock on TipRanks’ Stock Analysis page.